Home » Newsletters » BioWorld Science

BioWorld Science

April 7, 2017

View Archived Issues

Transfer of U.S. orphan drug designations for CAEL-101 to Caelum

Novartis exercises option to in-license ECF-843 for ophthalmic indications

U.S. breakthrough therapy designation for evinacumab in homozygous familial hypercholesterolemia

Immune-Onc collaborates with University of Texas on cancer immunotherapy

AnaptysBio initiates first-in-human trial of ANB-019

Myriad Genetics and BeiGene to develop companion diagnostics for BGB-290

Innocrin awarded second U.S. fast track designation for seviteronel

Achillion initiates phase II study of ACH-4471 in paroxysmal nocturnal hemoglobinuria

Aurinia outlines phase III plans for voclosporin in lupus nephritis

IBA Molecular and Mallinckrodt Nuclear Medicine create new company Curium

BioMed Realty and UC San Diego announce plans for new oncology research center

TRAIL receptor agonist ABBV-621 activity described for solid tumors and hematological cancers

Asceneuron cleared to begin phase I study of oral tau inhibitor ASN-120290

Envarsus, tacrolimus retard formulation, shows promise in heart transplantation

Phase III topline results on Trerief for Parkinsonism accompanying DLB

BioTime establishes AgeX Therapeutics subsidiary

Quiet Therapeutics describes tumor targeting with hyaluronic acid-coated lipid nanoparticles

Nanobiotix completes private placement of shares to support progress with NBTXR-3

Novel HIF-1 inhibitor, IDF-11774, suppresses tumor growth through regulation of cancer metabolism

Hefei PreceDo Pharmaceuticals discovers novel FLT-3 inhibitors

XW Laboratories patents gamma-hydroxybutyric acid prodrugs

Zhejiang Bossan Pharmaceutical describes new EGFR inhibitors

GlaxoSmithKline divulges novel anti-HIV compounds

Indiana University Research and Technology, Assembly Biosciences present HBV core protein modulators

Neuropilin-2 identified as a marker of prostate cancer-specific survival

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026